Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Role of Renal Vascular Reactivity in the Development of Renal Dysfunction in Compensated and Decompensated Congestive Heart Failure

V. Kratky, L. Kopkan, S. Kikerlova, Z. Huskova, M. Taborsky, J. Sadowski, F. Kolar, L. Cervenka,

. 2018 ; 43 (6) : 1730-1741. [pub] 20181123

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19012111

BACKGROUND/AIMS: Reduction of renal blood flow (RBF) is commonly thought to be a causative factor of renal dysfunction in congestive heart failure (CHF), but the exact mechanism of the renal hypoperfusion is not clear. Apart from the activation of neurohormonal systems controlling intrarenal vascular tone, the cause might be altered reactivity of the renal vasculature to endogenous vasoactive agents. METHODS: To evaluate the role of this mechanism, we assessed by an ultrasonic transient-time flow probe maximum RBF responses to renal artery infusion of angiotensin II (ANG II), norepinephrine (NE) and acetylcholine (Ach) in healthy male rats and animals with compensated and decompensated CHF. CHF was induced by volume overload achieved by the creation of the aorto-caval fistula (ACF) in Hannover Sprague-Dawley rats. RESULTS: Maximum responses in RBF to ANG II were similar in rats studied five weeks (compensated phase) and 20 weeks (decompensated phase) after ACF creation when compared to sham-operated rats. On the other hand, NE elicited larger maximum decreases in RBF in rats with CHF (five and 20 weeks post-ACF) than in sham-operated controls. We observed greater maximum vasodilatory responses to Ach only in rats with a compensated stage of CHF (five weeks post-ACF). CONCLUSION: Greater renal vasoconstrictor responsiveness to ANG II or reduced renal vasodilatation in response to Ach do not play a decisive role in the development of renal dysfunction in ACF rats with compensated and decompensated CHF. On the other hand, exaggerated renal vascular responsiveness to NE may be here a contributing causative factor, active in either CHF phase.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012111
003      
CZ-PrNML
005      
20210209103008.0
007      
ta
008      
190405s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000495391 $2 doi
035    __
$a (PubMed)30472713
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Krátký, Vojtěch $7 xx0249394 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, krtv@ikem.cz. Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic, krtv@ikem.cz.
245    14
$a The Role of Renal Vascular Reactivity in the Development of Renal Dysfunction in Compensated and Decompensated Congestive Heart Failure / $c V. Kratky, L. Kopkan, S. Kikerlova, Z. Huskova, M. Taborsky, J. Sadowski, F. Kolar, L. Cervenka,
520    9_
$a BACKGROUND/AIMS: Reduction of renal blood flow (RBF) is commonly thought to be a causative factor of renal dysfunction in congestive heart failure (CHF), but the exact mechanism of the renal hypoperfusion is not clear. Apart from the activation of neurohormonal systems controlling intrarenal vascular tone, the cause might be altered reactivity of the renal vasculature to endogenous vasoactive agents. METHODS: To evaluate the role of this mechanism, we assessed by an ultrasonic transient-time flow probe maximum RBF responses to renal artery infusion of angiotensin II (ANG II), norepinephrine (NE) and acetylcholine (Ach) in healthy male rats and animals with compensated and decompensated CHF. CHF was induced by volume overload achieved by the creation of the aorto-caval fistula (ACF) in Hannover Sprague-Dawley rats. RESULTS: Maximum responses in RBF to ANG II were similar in rats studied five weeks (compensated phase) and 20 weeks (decompensated phase) after ACF creation when compared to sham-operated rats. On the other hand, NE elicited larger maximum decreases in RBF in rats with CHF (five and 20 weeks post-ACF) than in sham-operated controls. We observed greater maximum vasodilatory responses to Ach only in rats with a compensated stage of CHF (five weeks post-ACF). CONCLUSION: Greater renal vasoconstrictor responsiveness to ANG II or reduced renal vasodilatation in response to Ach do not play a decisive role in the development of renal dysfunction in ACF rats with compensated and decompensated CHF. On the other hand, exaggerated renal vascular responsiveness to NE may be here a contributing causative factor, active in either CHF phase.
650    _2
$a acetylcholin $x farmakologie $7 D000109
650    _2
$a angiotensin II $x farmakologie $7 D000804
650    _2
$a zvířata $7 D000818
650    _2
$a srdeční selhání $x komplikace $7 D006333
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a noradrenalin $x farmakologie $7 D009638
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a arteria renalis $x účinky léků $x patofyziologie $7 D012077
650    _2
$a renální oběh $x fyziologie $7 D012079
650    _2
$a vazokonstrikce $x účinky léků $7 D014661
650    _2
$a vazodilatace $x účinky léků $7 D014664
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kopkan, Libor $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kikerlová, Soňa, $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $d 1978- $7 xx0256886
700    1_
$a Huskova, Zuzana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Taborsky, Milos $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland.
700    1_
$a Kolar, Frantisek $u Department of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Cervenka, Ludek $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00003064 $t Kidney & blood pressure research $x 1423-0143 $g Roč. 43, č. 6 (2018), s. 1730-1741
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30472713 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20210209102924 $b ABA008
999    __
$a ok $b bmc $g 1391421 $s 1050416
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 43 $c 6 $d 1730-1741 $e 20181123 $i 1423-0143 $m Kidney & blood pressure research $n Kidney Blood Press Res $x MED00003064
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options